Inventor
STAHL NEIL
US49 patents
Patents
49 patentsUS6927044B2Aug 9, 2005
IL-1 receptor based cytokine traps
REGENERON PHARMA133 citations99
US10787501B1Sep 29, 2020
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA224 citations98
US9540449B2Jan 10, 2017
Anti-PCSK9 antibodies with pH-dependent binding characteristics
REGENERON PHARMA57 citations98
US7435553B2Oct 14, 2008
Isolating cells expressing secreted proteins
REGENERON PHARMA104 citations98
US6919183B2Jul 19, 2005
Isolating cells expressing secreted proteins
REGENERON PHARMA88 citations98
US6472179B2Oct 29, 2002
Receptor based antagonists and methods of making and using
REGENERON PHARMA108 citations98
US5470952ANov 28, 1995
CNTF and IL-6 antagonists
REGENERON PHARMA47 citations96
US5844099ADec 1, 1998
Cytokine antagonists
REGENERON PHARMA87 citations95
US10975139B1Apr 13, 2021
Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA15 citations93
US10954289B1Mar 23, 2021
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA28 citations93
US10676530B2Jun 9, 2020
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor
REGENERON PHARMA14 citations93
US10669341B2Jun 2, 2020
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor
REGENERON PHARMA13 citations93
US10392439B2Aug 27, 2019
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
REGENERON PHARMA22 citations93
US7927583B2Apr 19, 2011
Receptor based antagonists and methods of making and using
REGENERON PHARMA11 citations93
US7083950B2Aug 1, 2006
High affinity fusion proteins and therapeutic and diagnostic methods for use
REGENERON PHARMA26 citations93
US6811780B2Nov 2, 2004
Methods of using cytokine antagonists to treat HIV infection and AIDS
REGENERON PHARMA49 citations93
US10501526B2Dec 10, 2019
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA11 citations92
US10081670B2Sep 25, 2018
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA10 citations92
US9771414B2Sep 26, 2017
Human antibodies to ebola virus glycoprotein
REGENERON PHARMA18 citations92
US7531172B2May 12, 2009
Methods of treating diseases with a VEGF antagonist
REGENERON PHARMA30 citations92
US9718872B2Aug 1, 2017
Human antibodies to middle east respiratory syndrome—coronavirus spike protein
REGENERON PHARMA18 citations91
US7351411B2Apr 1, 2008
Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
REGENERON PHARMA23 citations91
US6610510B1Aug 26, 2003
Morphogenic proteins
REGENERON PHARMA20 citations91
US7008781B1Mar 7, 2006
Method of enhancing the biological activity of ligands
REGENERON PHARMA16 citations83
US11530255B2Dec 20, 2022
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA3 citations73
US10829544B2Nov 10, 2020
Human antibodies to Ebola virus glycoprotein
REGENERON PHARMA2 citations73
US10598669B2Mar 24, 2020
Isolating cells expressing secreted proteins
REGENERON PHARMA1 citations73
US10261093B2Apr 16, 2019
Isolating cells expressing secreted proteins
REGENERON PHARMA1 citations73
US9389236B2Jul 12, 2016
Isolating cells expressing secreted proteins
REGENERON PHARMA3 citations73
US11732030B2Aug 22, 2023
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA2 citations72
US11485788B2Nov 1, 2022
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
REGENERON PHARMA2 citations72
US10406222B2Sep 10, 2019
Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein
REGENERON PHARMA4 citations72
US7361350B2Apr 22, 2008
Use of an IL-1 antagonist for treating arthritis
REGENERON PHARMA6 citations70
US5360740ANov 1, 1994
Assay system for degenerative muscle disease
REGENERON PHARMA9 citations65
US7417134B2Aug 26, 2008
IL-1 receptor based cytokine traps and method of using
REGENERON PHARMA2 citations63
US7285532B2Oct 23, 2007
Therapeutic method for treating bone formation diseases
REGENERON PHARMA2 citations63
US6767894B1Jul 27, 2004
Use of ciliary neurotrophic factor
REGENERON PHARMA5 citations63
US12251440B2Mar 18, 2025
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA0 citations62
US12152067B2Nov 26, 2024
Human antibodies to ebola virus glycoprotein
REGENERON PHARMA0 citations62
US5955290ASep 21, 1999
Assay systems using the CNTF signal transduction pathway
REGENERON PHARMA5 citations62
US12459991B2Nov 4, 2025
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
REGENERON PHARMA0 citations61
US12325752B2Jun 10, 2025
Immunoglobulin proteins that bind to NPR1 agonists
REGENERON PHARMA0 citations58
US6270981B1Aug 7, 2001
Methods of screening competitors of OB-R binding to SHP-2-SH2 peptides
REGENERON PHARMA2 citations57
US7083949B2Aug 1, 2006
Receptor based antagonists and methods of making and using
REGENERON PHARMA0 citations52
US6846908B2Jan 25, 2005
DCR-5 bone affecting ligand
REGENERON PHARMA0 citations52
US6660499B1Dec 9, 2003
DCR5, a BMP-binding protein, and applications thereof
REGENERON PHARMA0 citations52
US12103960B2Oct 1, 2024
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
REGENERON PHARMA0 citations51
US10072076B2Sep 11, 2018
Human antibodies to NAv1.7
REGENERON PHARMA1 citations51
US7241739B2Jul 10, 2007
Morphogenic protein
REGENERON PHARMA0 citations51